Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Zoster Vaccine (CHO Cell) in Adults Aged 40 Years and Above
NCT06447779Phase 3Active, not recruiting
- Sponsor
- MAXVAX Biotechnology
- Start
- Jul 2024
- Primary completion
- Mar 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Zoster vaccine recombinant in herpes zoster (HZ) (2 arms), sponsored by MAXVAX Biotechnology. Primary endpoint: Incidence of confirmed Herpes Zoster (HZ) Cases. Started Jul 2024; status: active, not recruiting.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT06447779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06447779.